Document:

Exhibit 10.2

 

 

 

 

DATED

 

 

 

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY
OF OXFORD

 

and

 

BLUE WATER VACCINES

 

 

 

 

 

 

AMENDMENT AGREEMENT

 

relating to BWV
Influenza Vaccine

 

 

 

     

     

    

 

THIS AMENDMENT AGREEMENT
is made on                                         2022
BETWEEN:

 

	(1)	THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD, whose administrative office
                                                   is at University Offices, Wellington Square, Oxford, OX1 2JD, United Kingdom (the “University”); and

 

	(2)	BLUE WATER VACCINE, a company whose registered
office is at 1013 Centre Rd, Suite 403-B New Castle Wilmington, Delaware, 19805 (the “Sponsor”),

 

each a “Party”
and collectively the “Parties”.

 

BACKGROUND

 

	(A)	The parties entered into an agreement on 19th
December 2019 to sponsor a research project on BWV Influenza Vaccine (the “Original Agreement”)
	 	 
	(B)	The parties have agreed to amend the Original Agreement as
set out in this agreement to extend the Project Period by 18 months and increase the funding by £53,500.
	 	 
	(C)	This agreement is supplemental to the Original Agreement

 

IN CONSIDERATION OF the mutual understandings contained
in this agreement, the parties agree as follows:

 

NOW IT IS AGREED as follows:

 

	1.	DEFINITIONS AND INTERPRETATION

 

	1.1	All terms and expressions in this agreement shall have the same meaning as that given to them in the Original Agreement.
	 	 
	1.2	The rules of interpretation of the Original Agreement shall apply to this agreement as if set out in this agreement save that references
in the Original Agreement to ‘this Agreement’ shall be construed as references to this agreement.
	 	 
	1.3	Unless the context otherwise requires, references in the Original Agreement to “this agreement” shall be to the Original
Agreement as amended by this agreement.

 

	2.	AMENDMENTS TO THE ORIGINAL AGREEMENT

 

	2.1	The Original Agreement shall be amended with effect on and from the Effective Date.
	 	 
	2.2	Clause 2.1 is deleted and replaced with:

 

“The Project will begin on the Project Start Date
and shall continue until 31st June 2024 or until any later date agreed by the Parties in writing, or until this Agreement
is terminated in accordance with its provisions (the “Project Period”). An additional 12 months extension may be granted
by the Sponsor upon a review by the Sponsor by 31st March 2024, and as agreed by the Parties.”

 

    Page 2 of 4

     

    

 

	2.3	The following paragraph is added to Schedule 2:

 

The Sponsor shall pay an additional £53,500 to University
within 30 days of full execution of this Amendment Agreement. The sum is exclusive of VAT, if applicable.

 

	3.	CONTINUITY

 

	3.1	The provisions of the Original Agreement shall, save as amended in this agreement, continue in full force and effect, and shall be
read and construed as one document with this agreement.

 

	4.	MISCELLANEOUS

 

	4.1	This agreement may be executed and delivered in any number of counterparts, each of which is an original and which, together, have
the same effect as if each party had signed the same document.

 

	5.	GOVERNING LAW AND JURISDICTION

 

	5.1	This Agreement shall be governed by English Law and the English Courts shall have exclusive jurisdiction
to deal with any dispute which may arise out of or in connection with this Agreement.

 

IN WITNESS of this Agreement, the Parties have executed
this Agreement through their duly authorised representatives.

 

    Page 3 of 4

     

    

 

	SIGNED
    for and on behalf of THE  	)	 	 
	CHANCELLOR MASTERS AND  	)	 	 
	SCHOLARS OF THE UNIVERSITY OF  	)	 	 
	OXFORD  	)	 	 
	 	 	 	/s/ Ana Serra Barros       	 
	Name: 	Ana Serra Barros	 	 	 
	Title:	Research Contracts Lead	 	 	 
	Date:	16 May 2022	 	 	 
	 	 	 	 	 
	SIGNED
    for and on behalf of BLUE  	)	 	 
	WATER
    VACCINES  	)	/s/ Joseph Hernandez       	 
	 	 	 	 
	Name:	JOSEPH HERNANDEZ	 	 	 
	Title:	CEO
	 	 	 
	Date:	5/16/2022	 	 	 

 

Page 4 of 4Exhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of [Date], between Leader Capital Holdings Corp., a Nevada
Corporation (the “Company”), and [Purchaser’s Name] (the “Purchaser”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), or Rule 504, Rule 506(b) promulgated thereunder, or Regulation S promulgated under Section
5 of the Securities Act, the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE
I

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings indicated in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 144. With respect to the Purchaser, any investment fund or managed account
that is managed on a discretionary basis by the same investment manager as the Purchaser will be deemed to be an Affiliate of the Purchaser.

 

“Business
Day” means any day except Saturday, Sunday and any day that shall be a federal legal holiday or a day on which banking institutions
in the State of Nevada are authorized or required by law or other governmental action to close.

 

“Closing”
means each closing of the purchase and sale of the Shares pursuant to this Agreement.

 

“Closing
Date” means each Business Day when this Agreement has been executed and delivered by the applicable parties thereto, and all
conditions precedent to the Purchaser’s obligations to pay the applicable Purchase Price have been satisfied or waived.

 

“Commission”
means the Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, $0.0001 par value per share.

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Liens”
means a lien, charge, security interest, encumbrance, rights of first refusal, preemptive right or other restriction.

 

    	 

    	 

    

 

“Losses”
means a lien, charge, security interest, encumbrance, rights of first refusal, preemptive right or other restriction.

 

“Per
Share Purchase Price” means $0.10 per Share.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.

 

“Purchase
Price” means [Purchase Price].

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to
time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Shares”
means up to [Number of shares] of restricted Common Stock issuable to the Purchaser pursuant to this Agreement.

 

ARTICLE
II

PURCHASE
AND SALE

 

2.1
Sale of Shares in Tranches. Subject to the terms and conditions of this Agreement, the Company may issue and sell to the Purchaser
and the Purchaser may purchase from the Company the Shares in the aggregate amount of up to [Number of Shares] in [number of Tranches]
separate tranches (each, a “Tranche”), each for the total number of Shares set forth on Exhibit B attached
hereto (the “Tranche Schedule”) under certain conditions and criteria to be fulfilled. Unless otherwise agreed to
by the Company, no Shares shall be available in any subsequent Tranches unless the Shares under the previous Tranches are purchased in
full on or before the dates set forth in the Tranche Schedule.

 

2.2
Closing. The purchase and sale of the Shares in each Tranche shall constitute a separate Closing pursuant to this Agreement. At
each Closing, the Purchaser shall purchase from the Company, and the Company shall issue and sell to the Purchaser, the Shares in such
Tranche pursuant to the Tranche Schedule. Upon satisfaction of the conditions set forth in Section 2.3, each Closing shall occur virtually,
unless otherwise agreed by the parties.

 

2.3
Closing Conditions.

 

(a)
At each Closing, the Company shall deliver to the Purchaser:

 

(i)
this Agreement duly executed by the Company; and

 

(ii)
a certificate evidencing the Shares purchased at such Closing registered in the name of the Purchaser.

 

    	2

    	 

    

 

(b)
At each Closing, the Purchaser shall deliver or cause to be delivered to the Company the following:

 

(i)
this Agreement duly executed by the Purchaser; and

 

(ii)
the respective portion of the Purchase Price by wire transfer to the account of the Company using the instructions attached hereto as
Exhibit A.

 

(c)
All representations and warranties of the other party contained herein shall remain true and correct as of the Closing Date and all covenants
of the other party shall have been performed if due prior to such date.

 

(d)
For the purposes of this Agreement, a delivery of book-entry Shares constitutes delivery of certificates. To avoid any ambiguity, the
parties are not obligated to re-execute the Agreement, in the event representations and warranties of each party are accurate as each
Closing Date.

 

ARTICLE
III

REPRESENTATIONS
AND WARRANTIES

 

3.1
Representations and Warranties of the Company. The Company hereby makes the following representations and warranties set forth
below to the Purchaser:

 

(a)
Subsidiaries. The information about the entirety of the Company’s subsidiaries is reported in the Company’s periodic
reports under the Exchange Act.

 

(b)
Organization and Qualification. The Company is duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite power and authority to own
and use its properties and assets and to carry on its business as currently conducted.

 

(c)
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder or thereunder. The execution and delivery of this
Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary
action on the part of the Company and no further consent or action is required by the Company. This Agreement has been (or upon delivery
will be) duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally and general
principles of equity.

 

(d)
Issuance of the Shares. The Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will be
duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on
transfer provided for in this Agreement.

 

(e)
Capitalization. The authorized capital stock of the Company presently consists of 600,000,000 shares of Common Stock, $0.0001
par value, and 200,000,000 shares of preferred stock, $0.0001 par value. The Company has 154,999,219 shares of Common Stock, and no shares
of preferred stock, issued and outstanding as of July 15, 2021. Except as set forth in the SEC Reports (as defined below), there are
no other outstanding options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to
issue additional shares of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock.

 

    	3

    	 

    

 

(f)
Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of
the Company, threatened against or affecting the Company before or by any court, arbitrator, governmental or administrative agency or
regulatory authority (federal, state, county, local or foreign) which adversely affects or challenges the legality, validity or enforceability
of any of this Agreement or the Shares.

 

(g)
Reports; Financial Statements. The Company has filed all reports required to be filed by it under the Securities Act and the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve (12) months preceding the date hereof, (the foregoing materials
being collectively referred to herein as the “SEC Reports”) on a timely basis or has timely filed a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates,
the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and
regulations of the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading.

 

(h)
Shell Company Status. The Company is not a “shell company” (as such term is defined in Rule 12b-2 under the Exchange,
as amended (17 CFR 240.12b-2)).

 

(i)
Insurance. The Company maintains no insurance.

 

(j)
Private Placement. Assuming the accuracy of the Purchaser representations and warranties set forth herein, no registration under
the Securities Act is required for the offer and sale of the Shares by the Company to the Purchaser as contemplated hereby in accordance
with the terms of this Agreement.

 

(k)
Neither the Issuer nor any of its affiliates (as defined in Rule 501 under the Securities Act) nor any person acting on its or their
behalf has engaged or will engage in any directed selling efforts (as defined in Regulation S) in connection with the offering of the
Shares and it has complied and will comply with the offering restrictions requirement of Regulation S.

 

3.2
Representations and Warranties of the Purchaser. The Purchaser represents and warrants as of the date hereof and as of the applicable
Closing Date to the Company as follows:

 

(a)
Organization; Authority. If the Purchaser is an entity, the Purchaser is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter
into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations thereunder. The execution,
delivery and performance by the Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary
corporate action on the part of the Purchaser. This Agreement, to which it is party has been duly executed by the Purchaser, and when
delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser,
enforceable against it in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

    	4

    	 

    

 

(b)
Investment Intent. The Purchaser understands that the Shares are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Shares as principal for its own account for investment
purposes only and not with a view to or for distributing or reselling such Shares or any part thereof, has no present intention of distributing
any of such Shares and has no arrangement or understanding with any other persons regarding the distribution of such Shares. The Purchaser
is acquiring the Shares hereunder in the ordinary course of its business. The Purchaser does not have any agreement or understanding,
directly or indirectly, with any Person to distribute any of the Shares.

 

(c)
Purchaser Status. At the time the Purchaser was offered the Shares, it was, and at the date hereof it is an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act. The Purchaser is not required
to be registered as a broker-dealer under Section 15 of the Exchange Act.

 

(d)
Experience of the Purchaser. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares, and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment
in the Shares and, at the present time, is able to afford a complete loss of such investment.

 

(e)
General Solicitation. The Purchaser is not purchasing the Shares as a result of any advertisement, article, notice, general solicitation
or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio
or presented at any seminar or any other general solicitation or general advertisement.

 

(f)
Residence. The office or offices of the Purchaser in which its investment decision was made is located at the address or addresses
of the Purchaser set forth on the signature page hereto.

 

(g)
Rule 144. Subject to Section 4.1(a), the Purchaser acknowledges and agrees that the Shares are “restricted securities”
as defined in Rule 144 promulgated under the Securities Act as in effect from time to time and must be held indefinitely unless they
are subsequently registered under the Securities Act or an exemption from such registration is available. The Purchaser has been advised
or is aware of the provisions of Rule 144, which permits limited resale of shares purchased in a private placement subject to the satisfaction
of certain conditions, including, among other things: the availability of certain current public information about the Company, the resale
occurring following the required holding period under Rule 144 and the number of shares being sold during any three-month period not
exceeding specified limitations.

 

(h)
Regulation S. Terms used in this Subsection 3(2)(a) have the meanings given to them by Regulation S.

 

(i)
The Purchaser (and each beneficial purchaser for whom it is acting) is purchasing the Shares as principal for its own account, not for
the benefit of any other person (other than any disclosed principal disclosed to the Company) and not with a view to the resale, distribution
or other disposition of all or any of the Securities, and it is not a “U.S. person” as defined in Regulation S under the
Securities Act, and confirms that the purchase of the Securities by the Purchaser is not in violation of any applicable laws of its jurisdiction
of residence.

 

    	5

    	 

    

 

(ii)
Purchaser represents, warrants and undertakes that neither the Purchaser, nor its affiliates (as defined in Rule 501 under the Securities
Act), nor any persons acting on its or their behalf has engaged or will engage in any directed selling efforts with respect to the Shares.

 

(iii)
The Shares have not been and will not be registered under the Securities Act, and may not be offered or sold within the United States
or to, or for the account or benefit of, U.S. persons except in accordance with Regulation S or pursuant to an exemption from the registration
requirements of the Securities Act. The Purchaser represents, warrants and undertakes that it has not offered or sold, and will not offer
and sell any Shares (a) as part of their distribution at any time and (b) otherwise until six months after each Closing Date applicable
to the respective portion of the Shares, except in accordance with Regulation S, and it has not and will not engage in any hedging transactions
involving the Shares unless in compliance with the Securities Act. The Purchaser also agrees that, at or prior to confirmation of sale
of Securities, it will have sent to each distributor, dealer, or person receiving a selling concession, fee or other remuneration that
purchases Securities from it during the distribution compliance period a confirmation or notice to substantially the following effect:

 

The
securities covered hereby have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”),
and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution
at any time or (ii) otherwise until six months after the later of the commencement of the Offering and the Closing Date, except in either
case in accordance with Regulation S under the Securities Act. No hedging transaction can be conducted with regard to the securities
except as permitted by the Securities Act. Terms used above have the meanings given to them by Regulation S.

 

ARTICLE
IV

OTHER
AGREEMENTS OF THE PARTIES

 

4.1
Transfer Restrictions.

 

(a)
The Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Shares other
than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the Purchaser, the Company may
require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to
the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Shares under the Securities Act. As a condition of transfer, any such transferee shall
agree in writing to be bound by the terms of this Agreement and shall have the rights of the Purchaser under this Agreement.

 

(b)
The Purchaser agrees to the imprinting, so long as is required by this Section 4.1(b), of the following legend on any certificate evidencing
Shares:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THESE SECURITIES MAY
NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH
RESPECT TO THE SECURITIES UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREUNDER AND, IN THE CASE OF A TRANSACTION EXEMPT
FROM REGISTRATION, UNLESS SOLD PURSUANT TO REGULATION S OR RULE 144 UNDER SUCH ACT OR THE ISSUER HAS RECEIVED DOCUMENTATION REASONABLY
SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER SUCH ACT.

 

    	6

    	 

    

 

(c)
The Purchaser agrees that the removal of the restrictive legend from certificates representing Shares as set forth in this Section 4.1
is predicated upon the Company’s reliance that the Purchaser will sell any Shares pursuant to either the registration requirements
of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom.

 

ARTICLE
V

MISCELLANEOUS

 

5.1
Fees and Expenses. Except as otherwise set forth in this Agreement, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all stamp and other taxes and duties levied in connection
with the sale of the Shares.

 

5.2
Entire Agreement. This Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and either delivered personally, e-mailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or
registered mail, postage prepaid, to such address(es) or e-mail address(es) set forth on the signature page hereto, and shall be deemed
to be given and received (i) when so delivered personally, (ii) when sent, with no mail undeliverable or other rejection notice, if sent
by e-mail, or (iii) three (3) business days after the date of mailing to the address. The address for such notices and communications
shall be as set forth on the signature pages attached hereto.

 

5.4
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case
of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waiver
is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a
continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

5.5
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

5.6
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of the Purchaser. The Purchaser may assign its rights under this Agreement to any Person to whom the Purchaser assigns or transfers any
Shares.

 

    	7

    	 

    

 

5.7
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.5.

 

5.8
Governing Law; Venue; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in the County of New York, New York, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Agreement), and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The parties hereby waive
all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then
the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney’s fees and other costs
and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

5.9
Execution. This Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and
by different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts
so executed and delivered shall be construed together and shall constitute one and the same agreement.

 

5.10
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.

 

[SIGNATURE
PAGE FOR COMPANY FOLLOWS]

 

    	8

    	 

    

 

[COMPANY’S
SIGNATURE PAGE]

 

IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	 	Leader
    Capital Holdings Corp.
	 	 	 
	 	By:	 
	 	Name:	Yi-Hsiu
    Lin
	 	Title:	CEO
    

 

	 	Address
    for Notice:
	 	 
	 	Room
    2708-09, Metropolis Tower, 
	 	10
    Metropolis Drive,
	 	Hung
    Hom, Hong Kong
	 	E-mail
    address: [redacted]

 

[SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	9

    	 

    

 

[PURCHASER’S
SIGNATURE PAGE]

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed by its authorized signatories as of
the date first indicated above.

 

	 	 
	Name:	 
	Title
    (if applicable):	 
	 	 
	Address
    for Notice:	 

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]